Abstract Mammalian with-no-lysine [K] Definite answer yet will require future investigation by tubular perfusion in mice with altered WNK kinase expression.
Introduction
Mammalian with-no-lysine [K] (WNK) kinases are a family of four serine-threonine protein kinases, WNK1-4, with an atypical placement of the catalytic lysine [46] . Mutations of two members, WNK1 and WNK4, in humans cause pseudohypoaldosteronism type II (PHA2), an autosomaldominant disease characterized by hypertension and hyperkalemia [44] . Mutations in the WNK1 gene are large deletions of the first intron leading to increased expression. Mutations in the WNK4 gene are missense mutations in the coding sequence outside the protein kinase domain. WNK1-4 are products of different genes that contain a conserved kinase domain in the amino terminus [38, 44, 46] . WNK1 is widely expressed in multiple spliced forms [46] . The full-length WNK1 is produced from the entire 28 exons (referred as Blong WNK1^(L-WNK1)) and has a ubiquitous distribution [44, 46] . A shorter WNK1 transcript encoding a polypeptide lacking the amino-terminal 1-437-amino acids of the long WNK1 is highly expressed in the kidney (kidney-specific (KS-WNK1)) [9, 22] . The KS-WNK1 is produced by replacing the first four exons with an alternative exon 4A, which encodes 30 amino acids unique to KS-WNK1. The remaining exons 5 through 28 are the same as the long transcript.
Based on results of studies over the past 12+years, it is generally accepted that increased Na + reabsorption through Na + -Cl − cotransporter (NCC) in the distal convoluted tubule (DCT) and Na
− cotransporter (NKCC2) in thick ascending limb of Henle's loop (TAL) plays important pathogenic mechanism for the phenotype of hypertension in patients with PHA2 [18] . However, how WNK1 and WNK4 regulate NCC and NKCC2 and how mutations of WNKs cause activation of the cotransporters have been highly controversial. Here, we review current state of literature on these subjects and discuss a unifying mechanism(s) for WNK kinases regulation of NCC-and NKCC2-mediated Na + transport and by which dysregulation in PHA2 causes hypertension.
WNK4 as a negative versus positive regulator of NCC and the mechanism of regulation by WNK1
Using Xenopus oocyte expression system, initial studies by several groups reported that WNK4 is a direct inhibitor of NCC independently of its kinase activity and that WNK1 activates NCC by antagonizing WNK4 inhibition of NCC [45, 47, 48] . The decrease in NCC activity caused by WNK4 was due to decreased cell-surface protein abundance. These initial findings of inhibition of NCC by WNK4 were supported by several subsequent studies using mammalian cultured cells [4] . Bacterial artificial chromosome (BAC) transgenic mice overexpressing WNK4 showed hypotension and decreased NCC abundance further supports the notion that WNK4 is an inhibitor of NCC in vivo [15] .
In contrast, biochemical studies have shown that WNK1 and WNK4 phosphorylate and activate oxidative-stress response kinase-1 (OSR1) and related ste20-related proline/ alanine-rich kinase (SPAK). Activated OSR1 and SPAK can phosphorylate NCC and other SLC12 family members of transporter, NKCC1 and NKCC2, and increase their function in cells by stimulating the intrinsic activity and/or surface abundance [1, 20, 27, 41, 42] . The notion that WNK1 and 4 both stimulates NCC and NKCC1/2 via phosphorylation and activation of intermediate kinases OSR1 and/or SPAK in vivo were supported by studies showing that Wnk4-null mice have hypotension and decreased NCC abundance in the kidney and diminished urinary excretion of Na + in response to hydrochlorothiazide [5, 33] . Wnk4-null mice also have decreased levels of phosphorylated SPAK in the kidney. Moreover, Spak knockout mice exhibited decreased NCC abundance and activity and that deletion of Spak abrogated hypertension and Na + retention in a mouse model of human PHA2 created by knock-in of PHA-causing Wnk4 mutation [8, 49, 50] . Overall, these studies provide compelling results to oppose the results suggesting that WNK4 inhibits NCC and to support the notion that both WNK1 and WNK4 stimulate NCC in vivo.
Kelch3 and cul3 regulate ubiquitination and degradation of WNKs providing support for a revised model that WNK1 and 4 both stimulate NCC While mutations of WNK1 and WNK4 are recognized important causes of PHA2, only~70 % affected PHA2 individuals could be explained by mutations of these two genes [11] .
Two recent studies reported that mutations of KLHL3 and CUL3 also cause PHA2 [3, 16] . KLHL3 and CUL3 encode kelch-like 3 (kelch3) and cullin3 (cul3) protein, respectively. Cul3 is one of the six cullins involved in the degradation of intracellular proteins by ubiquitination [10] . Ubiquitin ligase including cul3-based cullin-RING ubiquitin ligases, also known as E3 ligases, is a key element in the ubiquitin or proteasome system that transfers ubiquitin moieties to substrates. Cul3 serves as a scaffold for the catalytic module of a RING finger protein (Rbx1) and a ubiquitin-conjugating enzyme (E2). Cul3 also serves as a scaffold for substrate adaptor proteins containing BTB domains that facilitate proteinprotein interaction. The kelch-like (KLHL) proteins are a family of more than 40 substrate adaptor proteins that can function to connect cul3-RING ubiquitin ligase to its substrates [13] . KLHL proteins contain one BTB domain, one BTB and Cterminal kelch (Back) domain, and five to six kelch domains. Each kelch domain forms one blade of a 6-bladed β-propeller structure, which is also involved in the protein-protein interaction. Kelch3 binds to cul3-RING ubiquitin ligase via BTB domain and to its substrate WNK kinases via the β-propeller structured-kelch domains (Fig. 1) .
Findings that mutations of KLHL3 and CUL3 predicted to impair degradation of WNK kinase also cause PHA2 provide strong support for the notion that WNK1 and WNK4 stimulate NCC [3, 16, 30, 43] . To further support this notion, knock-in mice carrying PHA2-mimicking mutations in KLHL3 have increased abundance of WNK4 proteins and increased NCC activity [32] . Interestingly, PHA2 patients with mutations in KLHL3 or CUL3 have relatively more severe phenotypes than those with WNK1 or WNK4, which can be explained by the notion that mutations in KLHL3 or CUL3 increase the abundance of both WNK1 and WNK4 [32] . Overall, the preponderant data including many in vivo studies indicate that also been proposed (see below). The only study reporting WNK4 inhibits NCC in vivo using BAC transgenic mice [15] has been disputed by an independent study by Uchida's group [43] , in which they reported that overexpression of WNK4 using the same WNK4-containing BAC clone lead to activation, not inhibition, of NCC.
Relationship between WNK1 and WNK4 regulation of NCC
Another controversy surrounding WNK kinase regulation of NCC is the relationship between WNK1 and WNK4. The initial study by Yang et al. reported that WNK1 did not regulate NCC by itself but antagonizes WNK4 inhibition of NCC [47, 48] . Recent study showed that there are multiple L-WNK1 isoforms with alternative splicing of exons 9, 11, 12, and 26 [39] . L-WNK1 variant lacking only exon 11 (WNK1Δ11) is the most dominant form in the kidney. WNK1Δ11 activates NCC in the in vitro assay [6] . The study by Yang et al. used a L-WNK1 variant lacking both exons 11 and 12 (WNK1Δ11-12), which is relatively less abundant in the kidney tissue [6, 39] . Compared with WNK1Δ11, WNK1Δ11-12 is much less potent in activating NCC in vitro [6] . Moreover, the WNK1 cDNA construct used by Yang et al. carried a point mutation that inactivates WNK1 stimulation of NCC [6] , perhaps explaining the negative results reported by Yang et al. [47, 48] . Hadchouel et al. recently showed that mice with increased WNK1 expression mimicking human PHA2 disease have increased NCC activity and concluded that WNK1 does activate NCC in vivo via SPAK [40] . WNK1 and WNK4 interact and form heteromultimers in vitro [6, 35] . To reconcile with those early reports that WNK4 is inhibitory to NCC and in keeping with the notion that WNK1 activates NCC, a more recent report by Hadchouel, Gamba, and coworkers proposed a revised model that WNK1 activates SPAK to activate NCC in DCT, and that WNK4 working upstream to antagonize WNK1 activation of NCC [6] . The conclusion in the latter report that WNK4 antagonizes WNK1 was based on that Wnk4-KO did not reduce the activation of NCC caused by increased WNK1 expression in mice and that WNK4 forms heteromultimers with WNK1 to inhibit its function in vitro. This conclusion, however, did not take into account that several independent studies including results shown in their study have shown that NCC is markedly downregulated in Wnk4-KO mice [5, 6, 33] . Wnk4-KO should not lead to downregulation of NCC if WNK4 works upstream of WNK1 to inhibit NCC.
A unifying model of WNK kinase regulation of NCC Overall, current available data strongly support a model that WNK1 and WNK4 both contribute to stimulation of NCC via OSR1/SPAK in vivo (Fig. 2) . This model is based on results of in vivo studies showing that loss-of-function of WNK4 or SPAK as in Wnk4-KO or Spak-KO, respectively, reduces NCC activity [5, 33, 49] and that gain-of-function of WNK4 as in mice overexpressing WNK4 or knock-in mice carrying PHA2-mimicking mutations of Wnk4 or Klhl3 increases NCC activity [32, 43, 50] . Moreover, mice overexpressing WNK1 generated by PHA2-mimicking deletion of the first intron of Wnk1 exhibit increased NCC activity [40] . Regarding the results of the study by Hadchouel, Gamba, and coworkers [6] , because both WNK1 [31, 37] . The effect of K + loading on NCC is not mediated by aldosterone because the effect is opposite to the expected effect of aldosterone on NCC. An increase in plasma aldosterone enhances the abundance of NCC [14] . Moreover, downregulation of NCC by K + loading persists in mice with defective synthesis of aldosterone and in mice with knockout of SGK1, a downstream mediator of aldosterone [31, 37] ], would be expected to enhance NCC-mediated NaCl reabsorption due to favorable driving force (Fig. 3) 
Mechanism for regulation of NKCC2 by WNK kinases
In vitro biochemical and cell-based studies have provided evidence supporting the notion that activation of SPAK and/or OSR1 by WNK1 and WNK4 kinases also stimulate NKCC2-mediated Na + reabsorption in the thick ascending limb (TAL) of Henle's loop [1, 18, 20, 28, 42] . Whether OSR1, SPAK, or both is involved in vivo yet has been debated. Studies based on measurement of NKCC2 protein abundance in several SPAK loss-of-function mutant mouse models have produced apparent discrepant results [19, 26, 49] . Rafiqi et al. reported that total and phosphorylated NKCC2 protein abundance were decreased in homozygous knock-in mice carrying a loss-offunction Spak allele, support the role of SPAK in the stimulation of NKCC2 [26] . Another study yet showed that the abundance of phosphorylated NKCC2 was increased in SPAK-KO mice created by deletion of exons 9 and 10 of Spak gene [49] .
Authors in the latter study also found that OSR1 is more abundant than SPAK in TAL and that OSR1 is upregulated in TAL of SPAK-KO mice. They proposed that compensatory upregulation of OSR1 accounts for the increased NKCC2 abundance in their study. In a third study, McCormick et al. also found increased abundance of both total and phosphorylated NKCC2 in a separate mouse model of SPAK-KO mice created by gene-trap insertion [19] . In the study by McCormick et al., they also identified a smaller kidney-specific SPAK (KS-SPAK) isoform that can inhibit the function of full-length SPAK (FL-SPAK) in vitro. KS-SPAK is more abundant than FL-SPAK in TAL. Since both exons 9 and 10 deletion and gene-trap insertion are expected to inactivate FL-SPAK as well as KS-SPAK, McCormick et al. suggested that increased abundance of NKCC2 observed in the gene-trap and in exons 9 and 10-deleted mice is due to loss of a combined net inhibitory effect of KS-SPAK plus FL-SPAK in TAL. This proposed mechanism yet cannot fully explain the apparent discrepancy in the above three studies because both FL-SPAK and KS-SPAK should also be inactivated in the knock-in mouse model employed in the study by Rafiqi et al. [26] .
Of note, NKCC2 gene is alternatively spliced, and there are as many as six different NKCC2 isoforms in mice [12, 24] . Some splice variants are functionally inactive and may exert dominant-negative inhibition on the full-length variant [12, 24] . All six splice variants have identical amino-terminal amino acids that can be recognized by anti-phospho-NKCC2 antibodies [18] . Thus, abundance of phosphorylated NKCC2 should not be used as a sole indicator of NKCC2 activity. Recently, Cheng et al. revisited the question by direct measurement of NKCC2-mediated Na + reabsorption in isolated perfused TAL [7] . They found that, compared with that in tubules isolated from wild-type mice, NKCC2-mediated Na + reabsorption is markedly reduced in perfused TAL isolated from Spak-KO mice generated by deletion of exons 9 and 10 (expected to lack both FL-and KS-SPAK). These results indicate that the combined net effect of SPAK isoforms in TAL is stimulation of NKCC2-mediated Na + reabsorption. OSR1 likely also contributes to stimulation of NKCC2, though the relative contribution by SPAK and OSR1 remain unknown. Finally, high dietary K + intake also inhibits Na + reabsorption in TAL, which also contributes to enhanced distal Na + delivery for stimulation of K + secretion [36] . The mechanism for dietary K + intake and extracellular [K + ] to regulate NKCC2-mediated Na + reabsorption in TAL is likely similar to that for NCC in DCT (as shown in Fig. 3 
Summary and future perspectives
Since the first report in 2003, the mechanism of regulation of NCC by WNK kinases has gone through numerous twists and turns and multiple rounds of revision. Cumulative evidence to date based mostly on in vivo studies in mice has now provided a compelling model that WNK1 and WNK4 both contribute to stimulation of NCC. Because WNK kinases may multimerize, the relationship between regulation by WNK1 and WNK4, and potentially also by WNK3, in vivo remains unclear. ] may also affect WNK kinase activity and thus NCC phosphorylation and activity if the magnitude of changes is sufficient and fits within the dynamic range of regulation of NCC by WNK kinase cascade. Future investigation using tubular perfusion is required to address this question recent discovery that WNK kinases may function as an intracellular chloride sensor adds a new dimension to the physiological role of WNK kinases. While it is intriguing to postulate that chloride-dependent regulation of WNKs may underlie the mechanism of regulation of NCC and NKCC2 by extracellular K + , direct investigation by tubular perfusion in mice with altered WNK kinase expression will be paramount.
